Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy
By the numbers: Prostate cancer
Prostate Cancer: An Overview (Updated 2022)
(PDF) What’s new in prostate cancer research?
VIDEO
Future of Prostate Cancer: Breakthroughs, Treatments, and Holistic Approaches
Prostate Cancer Breakthrough Urine Test Avoids Unnecessary Biopsies
10 Must-Eat Foods To shrink Enlarged Prostate & 10 to Avoid"
Genetic Predisposition to Prostate Cancer & Relevance to Targeted Screening
SEPTEMBER IS PROSTATE CANCER AWARENESS MONTH
Prostate Cancer: From Diagnosis to Recovery
COMMENTS
Advances in Prostate Cancer Research - NCI
Find what's new in prostatecancerresearch, including current progress in improving biopsies and imaging for diagnosis, and in treating prostate cancerwith hormone therapy, immunotherapy, and targeted therapy. Selected NCI-supported programs are also described.
Fifteen-Year Outcomes after Monitoring, Surgery, or ...
In the United States in 2020, approximately 192,000 men received a diagnosis of prostatecancer and 33,000 died of the disease. 1 Since the U.S. Preventive Services Task Force updated its...
A Promising New Therapy for Advanced Prostate Cancer
Prostate cancer treatment stands on the brink of a major advance with the development of a new treatment that zeros in on cancer cells to destroy them. The therapy, called177Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface.
FDA approves new treatment for advanced prostate cancer
In June, the FDA approved a new treatment for the most advanced type of prostate cancer. Patients who have this condition, which is calledmetastaticcastration-resistantprostatecancer (mCRPC), have few therapeutic options, so the approval helps to fill an urgent need.
The Lancet Commission on prostate cancer: planning for the ...
Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy.
FDA Approves Relugolix for Advanced Prostate Cancer
In a large clinical trial, the drug, relugolix (Orgovyx), was shown to be more effective at reducing testosterone levels in men with advanced prostate cancer than another commonly used treatment, leuprolide (Lupron).
IMAGES
VIDEO
COMMENTS
Find what's new in prostate cancer research, including current progress in improving biopsies and imaging for diagnosis, and in treating prostate cancer with hormone therapy, immunotherapy, and targeted therapy. Selected NCI-supported programs are also described.
In the United States in 2020, approximately 192,000 men received a diagnosis of prostate cancer and 33,000 died of the disease. 1 Since the U.S. Preventive Services Task Force updated its...
Prostate cancer treatment stands on the brink of a major advance with the development of a new treatment that zeros in on cancer cells to destroy them. The therapy, called 177 Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface.
In June, the FDA approved a new treatment for the most advanced type of prostate cancer. Patients who have this condition, which is called metastatic castration-resistant prostate cancer (mCRPC), have few therapeutic options, so the approval helps to fill an urgent need.
Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy.
In a large clinical trial, the drug, relugolix (Orgovyx), was shown to be more effective at reducing testosterone levels in men with advanced prostate cancer than another commonly used treatment, leuprolide (Lupron).